BioNexus Gene Lab Corp Common stock Cash Flow Reinvestment Rate
BioNexus Gene Lab Corp Common stock cash flow reinvestment rate. BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Reinvestment Rate of 0.14x as of December 2022, reinvesting $66.93K (capex $17.03K plus investments $-49.90K) from operating cash flow of $474.47K. Explore BGLC debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of BioNexus Gene Lab Corp Common stock (2017–2022)
Cash flow reinvestment rate of BioNexus Gene Lab Corp Common stock from 2017 to 2022. Historical reinvestment intensity for BioNexus Gene Lab Corp Common stock across 4 annual periods. Explore BGLC capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
BioNexus Gene Lab Corp Common stock Cash Flow Reinvestment Rate by Year (2017–2022)
BioNexus Gene Lab Corp Common stock cash flow reinvestment rate by year from 2017 to 2022. Year-by-year capital reinvestment analysis for BioNexus Gene Lab Corp Common stock. For the full cash flow conversion analysis, see BioNexus Gene Lab Corp Common stock cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.93x | $504.67K | $544.03K | $54.17K | ▼ -98.3% |
| 2021 | 55.96x | $512.61K | $9.16K | $3.16K | ▲ +6082.7% |
| 2020 | 0.91x | $500.19K | $552.68K | $421.62K | ▼ -1.1% |
| 2017 | 0.92x | $326.90K | $357.22K | $314.82K | — |